

Material Safety Data Sheet ANSI Format

Conjugated Estrogens

Preparation Date 04-Dec-2006 Revision Date 31-Mar-2008 Revision Number 2

1. PRODUCT AND COMPANY IDENTIFICATION

Product Name Conjugated Estrogens
Common Name Conjugated Estrogens
Chomical Name Not applicable

Chemical Name Not applicable Synonyms Premarin

Product UsePharmaceutical productClassificationHormones - Estrogens

Supplier Wyeth

P.O. Box 8299

Philadelphia, PA 19101 USA. Telephone: 1-610-688-4400

Emergency Telephone Number Chemtrec USA, Puerto Rico, Canada 1-800-424-9300

Chemtrec International 1-703-527-3887

2. HAZARDS IDENTIFICATION

Emergency Overview

This is an active pharmaceutical ingredient that can affect body functions; handle with caution.

Appearance Pharmaceutical powderPhysical StateSolidOdor Not available

Potential Physical Hazards Powders and solids are presumed to be combustible.

Potential Health Effects

Eyes May cause mechanical eye irritation.

SkinNot availableInhalationNot available

Ingestion

The most common effects may include vaginal bleeding irregularities, change in menstrual flow, breast changes (tenderness, pain, enlargement, secretion, lumps), vaginal secretion, vaginal yeast infections, changes in reproductive organs, skin rash, joint pain, diarrhea.

vaginal yeast infections, changes in reproductive organs, skin rash, joint pain, diarrhea, dizziness, fatigue, and stomach/abdominal cramps/bloating. Increased risks of endometrial cancer, myocardial infarction, pulmonary emboli, deep vein thrombosis, coronary heart disease, stroke, venous thromboembolism, dementia, gallbladder disease, headache, and

mental depression, colitis, central nervous system effects.

May impair fertility. May cause harm to the unborn child. Excreted in breast milk. May cause

cancer.

Please see Patient Package Insert for further information.

Therapeutic Target Organ(s) Reproductive System.

Listed by NTP and IARC. Not listed by OSHA.

Potential Environmental Effects See Section 12.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Common Name	CAS-No	Composition
Congugated Estrogens	12126-59-9	100%

4. FIRST AID MEASURES

Eye Contact In the case of contact with eyes, rinse immediately with plenty of water for 15 minutes and seek

medical advice.

Skin ContactTake off contaminated clothing and shoes immediately. Wash off immediately with soap and

plenty of water. If skin irritation persists, call a physician.

Inhalation Move to fresh air. Artificial respiration and/or oxygen may be necessary. If symptoms persist,

call a physician.

Ingestion If symptoms persist, call a physician. Do not induce vomiting without medical advice. Never

give anything by mouth to an unconscious person.

5. FIRE-FIGHTING MEASURES

Flammable Properties Presumed to be a combustible particulate solid.

Extinguishing Media

Suitable Extinguishing Media

Unsuitable Extinguishing

Media

Use water spray, foam, dry chemical or carbon dioxide.

Do NOT use water jet.

Fire Fighting Evacuate area and fight fire from a safe distance. Cool closed containers exposed to fire with

water spray. In the event of fire and/or explosion do not breathe fumes.

Hazardous Combustion Products Carbon oxides, nitrogen oxides.

Protective Equipment and Precautions for Firefighters

In the event of fire, wear self-contained breathing apparatus and special protective equipment

for fire fighters.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions Refer to protective measures listed in Sections 7 and 8.

Environmental Precautions Prevent product from entering drains. Local authorities should be advised if a significant spill

cannot be contained.

Methods for Containment Not available

Methods for Cleaning up Take up mechanically and collect in suitable container for disposal. Clean contaminated

surface thoroughly. Avoid formation of dust and aerosols.

7. HANDLING AND STORAGE

Handling For personal protection see Section 8. Handle in accordance with good industrial hygiene and

safety practice. Skin should be washed after contact. Avoid formation of dust and aerosols.

Storage No special safety precautions required. Keep container tightly closed.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Common Name Exposure Guideline

Congugated Estrogens 0.15 mcg/m³

Risk Based Exposure Control

Classification

4

Engineering Controls Apply technical measures to comply with the occupational exposure guideline Fully contained

systems with no open handling

Personal Protective Equipment

Eye/face Protection Skin Protection Respiratory Protection Avoid contact with skin and eyes Provide eye protection based on risk assessment.

Wear nitrile or latex gloves. Wear protective garment. Base respirator selection on a risk assessment.

General Hygiene Considerations

When using, do not eat, drink or smoke. General industrial hygiene practice. Wash hands

before breaks and immediately after handling the product.

Other Limit access to only personnel trained in the safe handling of this material. Consult a health

and safety professional for specific PPE, respirator, and risk assessment guidance.

9. PHYSICAL AND CHEMICAL PROPERTIES

Pharmaceutical powder **Physical State** Solid **Appearance** Color Buff Odor Not available Not available **Odor Threshold Molecular Weight** 372.4 Not available Hq **Specific Gravity** Not applicable **Water Solubility** Soluble Not applicable Not applicable Solubility **Evaporation Rate Partition Coefficient** Not available Vapor Pressure Not applicable (n-octanol/water) **Boiling Point** Not applicable **Autoignition Temperature** Not applicable **Flash Point** Not available Method None **Melting Point** Not available **Flammability Limits Upper** Not applicable Lower Not applicable in Air **Explosion Limits Upper** Not applicable Lower Not applicable

Revision Date 31-Mar-2008 Conjugated Estrogens

10. STABILITY AND REACTIVITY

Chemical Stability Stable at room temperature.

Conditions to Avoid None under normal use.

Materials to Avoid No materials to be especially mentioned.

Hazardous Decomposition Products None under normal use.

Possibility of Hazardous Reactions None under normal use.

11. TOXICOLOGICAL INFORMATION

The following effects are based on the Active Pharmaceutical Ingredient.

Acute Toxicity

Congugated Estrogens

LD50 Oral >5000 mg/kg rats

IP 325 mg/kg rats IR 1740 mg/kg mice

Acute Dermal Irritation Not available

Primary Eye Irritation Severe irritation effects in rabbits.

Sensitization Not available

Medroxyprogesterone Acetate

LD50 Oral >6400 mg/kg rats

>4000 mg/kg mice >5 g/kg dogs

Acute Dermal Irritation Not a skin irritant.

Primary Eye Irritation Mild eye irritant.

Primary Eye Irritation Mild eye irritant.
Sensitization Not available

Multiple Dose Toxicity

Congugated Estrogens

No Toxicologic Effect See Carcinogenicity

Dose/Species/Study Length:

Medroxyprogesterone Acetate

No Toxicologic Effect See Carcinogenicity

Dose/Species/Study Length:

Maximum Tolerated Dose (MTD), Oral

Congugated Estrogens

Carcinogenicity In certain animal species, long-term continuous administration of estrogens increases the

frequency of cancers in the breast, cervix, liver, pancreas, testes, uterus, and vagina. Results of animal studies may not apply to humans because of the general hormonal differences of sex

steroids among species.

Genetic Toxicity No specific mutagenic information available.

Reproductive Toxicity No data available

Developmental Toxicity No evidence of teratogenic effects.

Medroxyprogesterone Acetate

Carcinogenicity In a two-year oral study in female rats, a dose-related increase in pancreatic islet cell tumors

occurred, and a decreased incidence of spontaneous mammary gland was observed in all treated groups. Dogs treated with MPA developed mammary nodules, some of which were malignant. In humans, results of a multinational case-control study in developing countries over a 9-year period indicated that the use of MPA did not increase the risk of breast cancer.

Not mutagenic in AMES Test. Non-mutagenic in the mouse micronucleus assay.

Genetic Toxicity
Reproductive Toxicity
Developmental Toxicity

Animal studies have reported no impairment of fertility in first or second generation studies. Studies in humans have shown that MPA may decrease intrauterine growth. No evidence of

teratogenic effects.

Congugated Estrogens

Target Organ(s) of Toxicity No data available

Medroxyprogesterone Acetate

Target Organ(s) of Toxicity No data available

12. ECOLOGICAL INFORMATION

The following effects are based on the Active Pharmaceutical Ingredient.

Chemical Fate Information

Congugated Estrogens

Mobility Not available

Biodegradability Considered to be biodegradable under aerobic conditions.

Stability in WaterNot availableBioaccumulationNot available

Medroxyprogesterone Acetate

Mobility Not available

Biodegradability Not readily biodegradable.

Stability in Water Not available Bioaccumulation Not available

Ecotoxicity

Congugated Estrogens

Microorganisms Inhibition > 150 mg carbon/liter

AlgaeNot availableDaphniaNot availableFishNot available

Medroxyprogesterone Acetate

MicroorganismsNot availableAlgaeNot availableDaphniaNot availableFishNot available

13. DISPOSAL CONSIDERATIONS

Waste Disposal Method Dispose of in accordance with local and national regulations.

14. TRANSPORT INFORMATION

Transport Information This material is not classified as hazardous for transport.

U.S. Department of Transport (DOT)

Canadian Transport of Dangerous Goods (TDG)

International Civil Aviation Organization (ICAO)

International Air Transport Association (IATA)

International Maritime Dangerous Goods (IMDG)/International

Maritime Organization (IMO)

Transport of Dangerous Goods by Rail (RID)

Not regulated

Not regulated

Transport of Dangerous Goods by Rail (RID)

Transport of Dangerous Goods by Road (ADR)

Transportation of Dangerous Goods via Inland Waterways

Not regulated

Not regulated

(ADN)

15. REGULATORY INFORMATION

USA

Federal Regulations

OSHA Regulatory Status

This material is not considered hazardous by the OSHA Hazard Communication Standard (29 CFR 1910.1200)

SARA 313

Section 313 of Title III of the Superfund Amendments and Reauthorization Act of 1986 (SARA). This product does not contain any chemicals which are subject to the reporting requirements of the Act and Title 40n of the Code of Federal Regulations, Part 372.

SARA 311/312 Hazardous Categorization

Acute Health Hazard No
Chronic Health Hazard Yes
Fire Hazard No
Sudden Release of Pressure Hazard No
Reactive Hazard No

This product does not contain any HAPs..

State Regulations

California Proposition 65

This product contains the following Proposition 65 chemicals:

Common Name	CAS-No	Туре
Congugated Estrogens	12126-59-9	Cancer, Developmental Toxicity

Revision Date 31-Mar-2008

Conjugated Estrogens

Canada

Not classified

WHMIS Hazard Class

Non-controlled

European Union

In accordance with EC directives or respective national laws, the product does not need to be classified nor labeled.

16. OTHER INFORMATION

Prepared By Wyeth Department of Environment, Health & Safety

Format This MSDS was prepared in accordance with ANSI Z400.1-2004.

List of References Product Package Insert Revision Summary Changes to Section 2

Disclaimer:

The information, data, recommendations, and suggestions appearing in this material safety data sheet (MSDS) and/or in materials regarding our active pharmaceutical ingredients (APIs) or products are based upon tests and data believed to be reliable as of the date of publication. NO REPRESENTATIONS OR WARRANTIES, EITHER EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR ANY OTHER WARRANTY IS MADE WITH REGARD TO THE INFORMATION PROVIDED IN THE MSDS, REGARDING THE API, OR THE PRODUCT TO WHICH THE INFORMATION PERTAINS. Accordingly, Wyeth will not be responsible for any damages resulting from use of, or reliance upon, this information as conditions of use are beyond our control. Users are responsible for assuring the safety of their workers and safe operating conditions, and for determining whether the API or product is suitable for their particular purposes. Users shall assume all risks of their use, handling, and disposal of the API and/or product in accordance with all appropriate and applicable regulations. This information relates only to the API or product designated herein, and does not relate to its use in combination with any other API, material, product, or process. No permission is granted for the use of any API or product in a manner that might infringe on existing patents.

End of MSDS